The effectiveness of Contrapain-10® (nefopam hydrochloride) in multimodal analgesia of dogs

Purpose of the research: to estimate the effectiveness of nefopam hydrochloride (Contrapain-10®) as a part of multimodal analgesia in pre- and intraoperative period of dogs, and to find out whether this medicine will reduce the number of anesthetics used during the intraoperative period. Materials and methods: the study included 34 dogs; 2 groups (n = 17) were formed from patients with diagnosed herniated discs of varying severity in different departments. All animals were subject to surgical treatment: group A (control group with nefopam hydrochloride) and B (experimental group without nefopam hydrochloride). For group A dogs in the preoperative period a non-opioid analgesic of central action, nefopam hydrochloride, was introduced into the multimodal analgesia scheme at a dosage of 0.3…0.5 mg/kg of body weight intramuscularly with an assessment of the analgesic effect. For dogs of group B (control) A standard multimodal analgesia protocol was used without the nefopam hydrochloride. During the intraoperative period, patients' pain levels were assessed using numerical hardware parameters (the main components of monitoring are ECG, frequency of respiratory movements, heart rate, noninvasive blood pressure, pulse oximetry, thermometry), as well as visual monitoring. Physiological parameters, pain and degree of sedation were assessed during the whole surgical operation and intermediate results were recorded every 30, 60, 90, 120, 150, 180 minutes. Estimation of clinical effectiveness of the medicine was evaluated based on the results of the pain assessment (from 1 to 5), general condition and values of vital parameters recorded during surgery. Results: Contrapain-10® promotes high-quality and safe anesthesia of patients both during surgery and in the postoperative period. At the same time, the consumption of opioid and non-opioid analgesics is minimal.